There are currently 957 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Birmingham, Alabama
Conditions: Neoplasms
Register for Updates
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
NCT03457493
Recruiting
The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine re... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/28/2025
Locations: UAB Advanced Imaging Facility, Birmingham, Alabama
Conditions: Parkinson Disease
Register for Updates
Cognitive Remediation Intervention to Prepare for Transition of Care
NCT05336201
Recruiting
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
02/28/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills
Register for Updates
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/taxol/pembro, Maintenance Olaparib/pembro
NCT05952453
Recruiting
this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama
Conditions: Ovarian Cancer
Register for Updates
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Recruiting
This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
02/27/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: O'Neal Comprehensive Cancer Center, Birmingham, Alabama
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
NCT05270525
Recruiting
This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up to 24 weeks participation.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
02/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: COPD
Register for Updates
Together in Recovery With Veterans Through Employment
NCT05388812
Recruiting
The purpose of this study is to help Veterans who have opioid use problems with gaining and maintaining meaningful employment. The investigators also want to know employment helps with other aspects of the Veteran's life including starting and staying on necessary medications, mental health needs, and feeling a part of society.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
02/26/2025
Locations: Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama
Conditions: Veterans With Opioid Use Disorder
Register for Updates
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
NCT03997786
Recruiting
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to \<18 years) before initiating the PK study in younger cohort (6 to \<12 years)
Gender:
ALL
Ages:
Between 6 years and 215 months
Trial Updated:
02/25/2025
Locations: Site 23, Birmingham, Alabama
Conditions: Moderate-to-severe Chronic Plaque Psoriasis
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham, Alabama
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Bodewell Products for the Treatment of Atopic Dermatitis
NCT05566262
Recruiting
This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/25/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Atopic Dermatitis
Register for Updates
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331
Recruiting
A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis. Subjects with prior DES implantation presenting with ISR lesions undergoing PCI will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or POBA on a 2:1 basis. Approximately 492 subjects will be enrolled in the randomized study in a... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
02/24/2025
Locations: Cardiology, PC - Princeton Baptist Medical Center, Birmingham, Alabama
Conditions: In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Register for Updates